RIMAG GROUP (02522) surged over 5%, and as of press time, the stock was up 4.4% to HK$14.72, with a trading volume of HK$210 million. On the news front, RIMAG GROUP announced on August 22 a share placement plan to issue 35 million shares at approximately 12.53% discount, raising net proceeds of about HK$562 million.

According to the announcement, approximately 40% of the net proceeds from the placement will be allocated to development in data and artificial intelligence fields, further strengthening the company's capabilities in medical imaging data mining, annotation, and cleansing services, as well as developing AI application platforms to provide comprehensive medical imaging workflow solutions. About 30% of the net proceeds will be used to continuously expand the company's medical imaging center business and enabling solution services through independent investment or mergers and acquisitions, aiming to secure more strategic strongholds in the domestic market while simultaneously expanding to overseas markets such as Hong Kong and Singapore.

Notably, RIMAG GROUP recently released its interim results for the six months ended June 30, 2025, showing revenue of RMB467 million, up 12.89% year-on-year; gross profit of RMB137 million; profit attributable to shareholders of RMB16.443 million, up 328.65% year-on-year; and basic earnings per share of RMB0.046.

The announcement stated that the group's newly established imaging center projects are expected to be gradually delivered and commence operations in the second half of 2025. Meanwhile, with the continued release of policy dividends from the national medical new infrastructure initiative and the gradual recovery of national medical equipment upgrade demand since the end of 2024, the enabling business revenue has achieved explosive growth.